ABCELLERA BIOLOGICS INC ABCL
ASignal's systematic analysis rates ABCL as Bearish.
Reflects the latest available analysis · analyzed Nov 4, 2026
The case on ABCL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.15x)
- High current and quick ratios indicating strong liquidity
- Significant cash reserves ($540.10M)
- Negative operating and gross margins
- Declining revenue growth (YoY -76.3%)
- Negative free cash flow (-$46.43M)
- Extremely high price-to-sales ratio (60.14x)
- Negative EV/EBITDA (-16.65x)
- Lack of Reddit sentiment data
See the full verdict on ABCL
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABCL
Most investors never get a second opinion, let alone several. ASignal runs ABCL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.